Compare NWTG & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWTG | GLMD |
|---|---|---|
| Founded | 2018 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 4.2M |
| IPO Year | 2022 | 2013 |
| Metric | NWTG | GLMD |
|---|---|---|
| Price | $1.27 | $4.63 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 28.8K | ★ 68.1K |
| Earning Date | 05-14-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.09 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,135,000.00 | N/A |
| Revenue This Year | $53.21 | N/A |
| Revenue Next Year | $40.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 136.14 | N/A |
| 52 Week Low | $0.70 | $0.41 |
| 52 Week High | $2.07 | $5.45 |
| Indicator | NWTG | GLMD |
|---|---|---|
| Relative Strength Index (RSI) | 48.93 | 75.44 |
| Support Level | $0.95 | $0.54 |
| Resistance Level | $1.79 | $5.45 |
| Average True Range (ATR) | 0.08 | 0.35 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 25.00 | 84.83 |
Newton Golf Co Inc is a technology-forward golf company engaged in designing, manufacturing, and selling performance golf equipment, including premium golf shafts and putters, and focuses on developing technology-driven golf products intended to enhance player performance. The company sells its products through e-commerce, distributors, wholesale customers, including pro-shops at golf courses and off-course retailers, sporting goods retailers, online retailers, third-party distributors, and through Club Champion Golf.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.